Pulmonary embolism - Epidemiology and Overview

Pulmonary Embolism: Overview and Epidemiology Definition and Pathophysiology A pulmonary embolism (PE) is a blockage of a pulmonary artery caused by material—typically a blood clot—that has traveled through the bloodstream from another site in the body. Think of it like debris traveling through a river and getting stuck at a narrow point downstream. When this blockage occurs, blood cannot flow properly through the affected portion of the lung, which can impair gas exchange and potentially compromise oxygen delivery to the body. The key thing to understand is that PE itself is not the original problem—it's a consequence of blood clots forming elsewhere and then traveling. This is why understanding where PEs originate is so important. Origin: Where Do Most Pulmonary Emboli Come From? The vast majority of pulmonary emboli originate from blood clots in the deep veins of the legs, a condition called deep vein thrombosis (DVT). A clot forms in these deep leg veins, breaks free, and travels through the venous system into the right side of the heart, which then pumps it into the pulmonary arteries in the lungs where it becomes trapped. This is why assessment of DVT risk is critical in PE prevention and diagnosis. When a patient has risk factors for clotting (like recent surgery, immobility, or hypercoagulability), DVT prophylaxis becomes important even if no PE has occurred yet. Who Gets Pulmonary Embolism? Epidemiology and Risk Age and Sex Distribution Pulmonary embolism affects both men and women at similar rates, but the incidence increases substantially with age. This age-related increase is one of the most consistent epidemiological findings in PE. Specifically, people older than 70 years experience venous thromboembolism (which includes both DVT and PE) at approximately three times the rate of those aged 45 to 69 years. Several factors contribute to this dramatic increase: Reduced physical activity: Immobility increases clot risk by promoting venous stasis (blood pooling) Higher obesity rates: Obesity is an independent risk factor for thromboembolism Age-related physiological changes: Older adults have changes in their coagulation system that favor clot formation <extrainfo> The global incidence of PE is approximately 10 million cases per year, though this number varies based on different population studies and definitions used. </extrainfo> Public Health Impact: Why PE Matters Understanding the burden of PE on public health helps underscore why this condition is clinically important: Mortality in the United States: PE is the primary cause of 10,000 to 12,000 deaths annually in the US It contributes to an additional 30,000 to 40,000 deaths per year (meaning it's a contributing factor to death, not the sole cause) This makes PE a significant public health problem—more people die from PE each year than from many other commonly discussed conditions. Prognosis and Case Fatality Rates: When we talk about case fatality rates, we're describing what percentage of people diagnosed with a condition die from it at specific time points. For venous thromboembolism overall: At 30 days: 10% case fatality rate At 3 months: 15% case fatality rate At 1 year: Up to 20% case fatality rate When PE specifically leads to hospitalization, the short-term mortality is somewhat lower: a 5% to 10% case fatality rate. The difference suggests that the most severe, immediately life-threatening PEs are more likely to be fatal before reaching the hospital, while hospitalized patients receive treatment that improves survival. The key takeaway is that PE is a serious condition with significant mortality, but prognosis depends on severity and how quickly treatment is initiated.